Advances in Immune Tolerance Induction in Enzyme Replacement Therapy

Area of Science:

• Biochemistry
• Genetics
• Immunology

Background:

• Inborn errors of metabolism (IEMs) are genetic disorders impacting metabolic pathways, significantly affecting patient health and survival.
• Enzyme replacement therapy (ERT) is a key treatment for many IEMs, particularly lysosomal storage disorders (LSDs).
• A major hurdle in ERT is the development of high antibody titers, which can limit treatment effectiveness.

Purpose of the Study:

• To review advancements in immune tolerance induction (ITI) for IEMs treated with ERT.
• To assess the efficacy of immunomodulation strategies in mitigating antibody development against ERT.
• To analyze clinical and preclinical trial data on ITI modalities in the context of IEMs, especially LSDs.

Main Methods:

• Comprehensive literature review of clinical and preclinical trials.
• Analysis of immunomodulation strategies used concurrently with ERT.
• Evaluation of outcomes related to antibody development and treatment efficacy.

Main Results:

• Immunomodulation strategies have shown promise in inducing immune tolerance to ERT.
• Concurrent administration of immunomodulation and ERT decreases IgG antibody development compared to ERT alone.
• ITI has demonstrated significant improvements in ERT efficacy and overall survival rates in IEM patients.

Conclusions:

• Immune tolerance induction is a crucial strategy for overcoming ERT-associated immunogenicity in IEMs.
• Further research and clinical application of ITI can enhance the long-term success of ERT for LSDs and other IEMs.
• Optimizing ITI approaches is vital for improving patient well-being and survival in the field of metabolic genetics.